

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S  
Form 6-K  
December 02, 2009

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K  
-----

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934

December 02, 2009

-----  
NOVO NORDISK A/S  
(Exact name of Registrant as specified in its charter)

NOVO ALLE  
DK-2880, BAGSVAERD  
DENMARK  
(Address of principal executive offices)

-----  
Indicate by check mark whether the registrant files or will file annual reports  
under cover of Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in  
connection with Rule 12g-32(b):82-\_\_\_\_\_

TRANSACTION IN OWN SHARES

STATUS REGARDING NOVO NORDISK'S HOLDING OF OWN SHARES

In continuation of the company's announcement dated 7 August 2009 concerning  
Novo Nordisk's share repurchase programme, and pursuant to Section 29 of the  
Danish Securities Trading Act, this is to report that as of today, Novo Nordisk

## Edgar Filing: NOVO NORDISK A S - Form 6-K

A/S (NYSE:NVO) and its wholly-owned affiliates own more than 5% of the total share capital in Novo Nordisk A/S.

As per 1 December 2009, Novo Nordisk A/S and its wholly-owned affiliates own 31,063,977 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 31,063,977 or 5.0% of the total share capital.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 29,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit [novonordisk.com](http://novonordisk.com).

Further information:

Media:

Mette Kruse Danielsen  
Tel: (+45) 4442 3883  
[mkd@novonordisk.com](mailto:mkd@novonordisk.com)

Investors:

Mads Veggerby Lausten  
Tel: (+45) 4443 7919  
[mlau@novonordisk.com](mailto:mlau@novonordisk.com)

Kasper Roseeuw Poulsen  
Tel: (+45) 4442 4471  
[krop@novonordisk.com](mailto:krop@novonordisk.com)

In North America:

Sean Clements  
Tel: (+1) 609 514 8316  
[secl@novonordisk.com](mailto:secl@novonordisk.com)

In North America:

Hans Rommer  
Tel: (+1) 609 919 7937  
[hrmm@novonordisk.com](mailto:hrmm@novonordisk.com)

Company Announcement no 71 / 2009

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: December 02, 2009

NOVO NORDISK A/S

-----  
Lars Rebien Sorensen,  
President and Chief Executive Officer